Robot-assisted Minimally Invasive Thoraco-laparoscopic Esophagectomy Versus Minimally Invasive Esophagectomy for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).
This study compares two advanced types of minimally invasive surgery for esophageal cancer to see which one removes more lymph nodes. The goal is to find out if using a robotic system helps doctors perform a more thorough and effective operation than standard minimally invasive surgery.
You might be able to join if you are between 18 and 90 years old, have a specific type of operable esophageal or gastroesophageal junction cancer, and are well enough to carry out daily activities. People with certain other cancer types, tumors in the upper neck, or previous right-sided chest surgeries cannot participate.
Participants are randomly placed into one of two groups to receive either robotic-assisted surgery or standard minimally invasive surgery to remove the cancer. Doctors will then compare how well each method works, looking closely at things like lymph node removal, recovery, and overall quality of life.
This study is currently recruiting participants in Mainz, Germany, and will follow patients for up to five years after their procedure.
- 1Comparing robotic surgery to standard minimally invasive surgery for esophageal cancer
- 2Measuring which technique removes more lymph nodes and offers the best recovery
- 3Open to adults aged 18 to 90 with specific types of resectable cancer
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.